Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wells Fargo & Company MN lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 51.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,939 shares of the company's stock after purchasing an additional 7,487 shares during the period. Wells Fargo & Company MN's holdings in Kymera Therapeutics were worth $883,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. ExodusPoint Capital Management LP acquired a new position in Kymera Therapeutics in the 4th quarter valued at about $568,000. Geode Capital Management LLC boosted its holdings in Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock valued at $44,484,000 after purchasing an additional 52,263 shares during the period. Franklin Resources Inc. grew its position in shares of Kymera Therapeutics by 30.3% during the 4th quarter. Franklin Resources Inc. now owns 38,367 shares of the company's stock worth $1,544,000 after purchasing an additional 8,927 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after buying an additional 688,967 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in shares of Kymera Therapeutics by 14.1% in the fourth quarter. Schroder Investment Management Group now owns 163,896 shares of the company's stock valued at $6,444,000 after buying an additional 20,204 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Finally, Stephens restated an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Stock Up 1.7 %

Shares of KYMR stock opened at $34.27 on Thursday. The firm has a market capitalization of $2.23 billion, a P/E ratio of -14.65 and a beta of 2.22. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27. The stock's fifty day simple moving average is $29.68 and its 200 day simple moving average is $38.40.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.